Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study.
H Nokihara, T Hida, M Kondo, YH Kim, K Azuma… - 2016 - ascopubs.org
… Background: ALC showed … ) of ALC to CRZ in ALK+ NSCLC patients (pts) without prior
ALK inhibitor treatment. Methods: ALK+ NSCLC pts were randomized 1:1 either to receive ALC (…
ALK inhibitor treatment. Methods: ALK+ NSCLC pts were randomized 1:1 either to receive ALC (…
MA07. 03 alectinib (ALC) versus crizotinib (CRZ) in ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from phase III study (J-ALEX)
Y Kim, T Hida, H Nokihara, M Kondo, K Azuma… - Journal of Thoracic …, 2017 - jto.org
… determining therapeutic strategy for ALK+ NSCLC patients (pts)… ALC to CRZ in ALK-inhibitor
naïve ALK+ NSCLC. Methods: ALK+ NSCLC pts were randomized 1:1 either to receive ALC …
naïve ALK+ NSCLC. Methods: ALK+ NSCLC pts were randomized 1:1 either to receive ALC …
Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
N Karachaliou, M Fernandez Bruno… - OncoTargets and …, 2019 - Taylor & Francis
… for ALK+ NSCLC previously treated with crizotinib. The main aim of this review is to assemble
on the efficacy of alectinib for the treatment of ALK+ NSCLC, … of ALK+ lung cancer patients. …
on the efficacy of alectinib for the treatment of ALK+ NSCLC, … of ALK+ lung cancer patients. …
Alectinib for ALK-positive non-small-cell lung cancer
A Rossi - Expert review of clinical pharmacology, 2016 - Taylor & Francis
… the efficacy and to evaluate the activity and tolerability of alectinib in ALK-rearranged advanced
NSCLC. To date, alectinib provides a very promising option for this subgroup of patients. …
NSCLC. To date, alectinib provides a very promising option for this subgroup of patients. …
[HTML][HTML] Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study
R Dziadziuszko, TS Mok, DR Camidge… - Annals of …, 2018 - annalsofoncology.org
… -ALK variant groups in both tissue and plasma BEPs for ALC- and CZ-treated pts (Table).
Median DoR was similar for EML4-ALK variants 1, 2 and 3 in the ALC … of ALC vs CZ in ALK+ …
Median DoR was similar for EML4-ALK variants 1, 2 and 3 in the ALC … of ALC vs CZ in ALK+ …
Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
T Vavalà, S Novello - Therapeutic advances in medical …, 2018 - journals.sagepub.com
… concentration of 0.616 ng/ml reported by Costa and colleagues 39 ) and corroborates the
reported activity of alectinib also in ALK-positive NSCLC patients with leptomeningeal disease. …
reported activity of alectinib also in ALK-positive NSCLC patients with leptomeningeal disease. …
… overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.
S Peters, TSK Mok, SM Gadgeel, R Rosell… - 2020 - ascopubs.org
… the most common ALK TKI received after first-line ALC (7.2… ALK TKI to demonstrate a
clinically meaningful improvement in OS vs CRZ in ALK+ NSCLC (5-year survival rate: 62.5%, ALC …
clinically meaningful improvement in OS vs CRZ in ALK+ NSCLC (5-year survival rate: 62.5%, ALC …
[HTML][HTML] Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)
S Novello, J Mazieres, IJ Oh, J De Castro… - Annals of …, 2017 - annalsofoncology.org
… Alectinib (ALC) has shown systemic and CNS efficacy in phase II trials of previously treated
ALK+ NSCLC … efficacy and safety of ALC vs standard relapse chemotherapy (CT) in ALK+ …
ALK+ NSCLC … efficacy and safety of ALC vs standard relapse chemotherapy (CT) in ALK+ …
… from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).
H Yoshioka, T Hida, H Nokihara, M Morise, YH Kim… - 2021 - ascopubs.org
… ALK-inhibitor naïve ALK+ NSCLC demonstrated superior progression-free survival (PFS) in
Japanese patients randomized to the ALC, … Facility (IRF) (Hida et al., Lancet 2017). The final …
Japanese patients randomized to the ALC, … Facility (IRF) (Hida et al., Lancet 2017). The final …
[PDF][PDF] MA07. 02 updated efficacy and safety data from the phase 2 NP28761 study of alectinib in ALK-positive non-small-cell lung cancer
… determining therapeutic strategy for ALK+ NSCLC patients (pts)… ALC to CRZ in ALK-inhibitor
naïve ALK+ NSCLC. Methods: ALK+ NSCLC pts were randomized 1:1 either to receive ALC …
naïve ALK+ NSCLC. Methods: ALK+ NSCLC pts were randomized 1:1 either to receive ALC …
相关搜索
- untreated advanced alk nsclc alectinib alc
- alk nsclc alectinib phase
- crizotinib crz alectinib alc
- alk nsclc patients
- subgroup analysis alectinib alc
- patients with advanced alk positive nsclc
- canadian population alk inhibitor alectinib
- nsclc ansclc eml4 alk variant
- np28673 and np28761 alectinib in alk
- previously treated alk alectinib in patients
- non-small cell lung cancer alectinib alc
- alk inhibitor alectinib alc
- phase iii alex study alectinib alc
- final os analysis alectinib alc
- alk nsclc progression on crizotinib
- pooled efficacy alectinib in alk